Landmark 218 · Trial in people
MOST-ABLE: oral semaglutide (Osaka)
Will tell us whether a daily semaglutide tablet slows the decline in movement in 99 people over 48 weeks, compared with placebo.
In short
A 99-person Japanese Phase 2 tests whether a daily semaglutide tablet slows motor decline; no results yet.
- What it is
- Trial in people
- Outcome
- Result due Mar 2027
- When
- 2023–2027
- Size
- 99 people · Phase 2
- Approach
- Look beyond the brain
- Research lane
- Metabolic drug repurposing
- Trial registry
- jRCT2051230090
- Last checked
- 19 Oct 2026
The research record
This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".
Who
University of Osaka Hospital (Yasuyoshi Kimura and Toru Koda, per a search summary of the registry), funded by Japan's AMED. Registered as jRCT2051230090.
What is being tested
Oral semaglutide, a GLP-1 drug in the class that diabetes risk (landmark 216) motivated. It is one of the four small trials in landmark 189. Design: double-blind, placebo-controlled, 99 people (Hoehn and Yahr 1–2.5), 1:1:1 to 7 mg, 14 mg or placebo daily, added to usual treatment. Dosing is 36 weeks. First enrolment 6 November 2023. Registry status: "Not Recruiting" (last modified 2 December 2025).
What would count as success
A smaller worsening of off-state MDS-UPDRS Part III (motor score) at 48 weeks than on placebo.
Sources
- jRCT2051230090 (read 18 Oct 2026)
- Protocol: BMJ Open 2025;15:e112318, DOI 10.1136/bmjopen-2025-112318 (full text blocked; details in landmark 189)
- Not yet verified: a stated completion date (expected 2027-03 is my estimate from 48-week follow-up after 2025-26 dosing); the "8 sites" count (the registry names only Osaka); any results (none found 19 Oct 2026; an AMED post-project report dated May 2026 turned up in search but was not read).
How it connects
Built on
- builds on Semaglutide Phase 2 trials (Oslo, MOST-ABLE) · 2019
Led to
None recorded.